科济药业-B：年度业绩公告截至2024年12月31日止年度

CARsgen Therapeutics Holdings Limited 20241231 2024123120231231 1. 2024123139.4賽愷澤®BCMA CAR-T20241231賽愷澤®75CAR-T 2. 2024123114.7 3. 202412317982023123174850202312313122920241231260(i)2023123166219620241231466(ii)202412311520231231 20241231(1)7892023123173356(i)(ii)(iii)(iv) 4. 202412311,479202312311,85037120251,0802028 (1) 賽愷澤®CT053 賽愷澤®B(BCMA)CAR-T202431(NMPA)賽愷澤®2024223(R/RMM)3000963.SZ賽愷澤®賽愷澤®20241231賽愷澤®23200154賽愷澤®II29(EHA)66(ASH)賽愷澤® CT041 Claudin18.2(CLDN18.2)CAR-T(GC/GEJ)II(NCT04581473)(IRC)(PFS)PFSIINMPACDE(BTD)(CT041-CG4006, NCT03874897)20246Nature Medicine202462024(ASCO)(PC)CT041-CG4006CT041-ST-01Journal of ClinicalOncology Claudin18.2I(CT041-ST-05,NCT05911217)(CT041-CG4010NCT06857786)20241031FDA CAR-T THANK-uCAR®CAR-TTHANK-uPlus™THANK-uCAR®CAR-TNKG2A THANK-uCAR®BCMACAR-TCT0590IIT20241266ASHCT0590BCMANKG2ACAR-TA First-in-HumanStudy of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy TargetingBCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma CAR-TBCMAR/RMM(R/R PCL)CT059X(THANK-u Plus™)CD19/CD20BKJ-C2219(THANK-uPlus™)CD38(AML)KJ-C2320(THANK-uCAR®)KJ-C2114(THANK-uPlus™)N K G2D LK J - C2526(THANK-u Plus™) I. 1. CAR-TCAR-TCAR-T 2. CAR-TCAR-T 2024賽愷澤®CT0533賽愷澤®賽愷澤® C T 0 7 1GPRC5DCARcelerate®CT071(CT041)GC/GEJII(CT041-ST-01, NCT04581473)IRCPFSCAR-TIGC/GEJI C A R - TTHANK-uCAR®CAR-TTHANK-u Plus™CAR-TBCMAR/R MMR/R PCLCT0590(THANK-uCAR®)BCMAR/R MMR/R PCLCT059X(THANK-u Plus™)CD19/CD20BKJ-C2219(THANK-u Plus™)CD38AMLKJ-C2320(THANK-uCAR®)KJ-C2114 (THANK-u Plus™)NKG2DLAMLKJ-C2526(THANK-u Plus™) 1. 2.II 3.SZ000963HK Inno.N Corporation195940 4.CT0590 賽愷澤®CT053BCMA CAR-T 賽愷澤®R/R MMBCMA CAR-TBCMA(scFv)CARCAR-TT 202431NMPA賽愷澤®2024223R/R MM320231賽愷澤®200751,025賽愷澤®賽愷澤®20241231賽愷澤®23200154 賽愷澤® 賽愷澤®LUMMICAR STUDY 120241266ASH2BCMACAR-TSubgroup Analyses of Phase 2 Study: Evaluating the Efficacy of FullyHuman BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patientswith Relapsed/Refractory Multiple Myeloma LUMMICAR-1202461529EHABCMACAR-T2Phase 2 study of fullyhuman BCMA-targeting CAR-T cells (zevorcabtagene autoleucel) in patientswith relapsed/refractory multiple myeloma102賽愷澤®(ORR)92.2% (94/102)(VGPR)91.2% (93/102)(CR)(sCR)71.6% (73/102) 20231265ASHLummicar1I3Three-Year Follow-Up on Efficacy andSafety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucelin Chinese Patients with Relapsed or Refractory Multiple MyelomaI/II(LUMMICAR-1, NCT03975907)I3 20241031FDALUMMICAR-2 18A.08(3) CT041Claudin18.2 CAR-T Claudin18.2CAR-TClaudin18.2GC/GEJPCClaudin18.2GC/GEJPCCAR-TClaudin18.2CAR-TCAR-T II(CT041-ST-01, NCT04581473)IRCPFS2025NMPANDA P CI( C T041- S T -05NCT05911217)GC/GEJCT041-CG4010NCT06857786 C T041- C G4006202463Nature MedicineClaudin18.2 CAR-TIClaudin18.2-specific CAR T cells ingastrointestinal cancers: Phase 1 trial final results202462024ASCOGC/GEJn=5951(DCR)54.9% (28/51)96.1% (49/51) 20245CT041Safety and Efficacy of CT041 in PatientsWith Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of TwoEarly-Phase TrialsJournal of Clinical OncologyI/IbCT041-CG4006CT041-ST-01 20242Claudin18.2-CARTMetastatic gastric cancer target lesion complete response withClaudin18.2-CAR T cellsJournal for ImmunoTherapy of Cancer28 20239NCT04581473NCT03874897Journal ofHematology & OncologyCT041 CAR-TClaudin18.2CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer I b / I I( C T 0 4 1 - S T - 0 1NCT04581473)Ib2022ASCOCLDN18.2 CAR T(CT041)lb/llSafety, Tolerability and Preliminary EfficacyResults in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinomafrom a Phase lb/ll Study of CLDN18.2 CAR T-cell therapy (CT041) 1b/2CT041-ST-02NCT04404595GC/GEJ2FDA1b2024ASCO GICLDN18.2TELIMYN18.2 1bCLDN18.2Chimeric Antigen Receptor T Cell Therapy for Patients with Advanced Gastric andPancreatic Adenocarcinoma: Results of ELIMYN18.2 Phase 1b Clinical Trial GC/GEJ20209FDAClaudin18.2GC/GEJ20221FDARMATII20252NMPACDEClaudin18.2GC/GEJ MRNAModerna, Inc.Claudin18.2 mRNA2023 18A.08(3) CT011GPC3 CAR-T CT011CAR-T(HCC)GPC3CAR-THCC 20237CAR-GPC3 TCombined local therapy and CAR-GPC3T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concepttreatment strategyCancer CommunicationGPC3 CAR-THCC7 20241CT011NMPAINDGPC3IIIa 18A.08(3)CT011 CT071–GPRC5D CAR-T CT071CARcelerate®GPRC5DCAR-TR/R MM(R/R pPCL)(scFV) CARcelerate®CT07130CAR-T CT071 IIT(NCT05838131)20241266ASHGPRC5DCAR-TCT071GPRC5D-Targeted CAR T-Cell TherapyCT071 for the Treatment of Refractory/Relapsed Multiple Myeloma R/R MMR/R PCL(NCT05838131)2024629EHAGPRC5DCAR-T(CT071)(RRMM)First-in-human study of GPRC5D-targetedCAR T cells (CT071) with an accelerated manufacturing process in patientswith relapsed/refractory multiple myeloma (RRMM) ( N D M M )(NCT06407947)CT071202311FDAINDR/R MMR/R pPCL FDACT071 18A.08(3)CT071 CAR-T THANK-uCAR®CAR-TTHANK-uPlus™THANK-uCAR®CAR-TNKG2A CT0590THANK-uCAR®BCMACAR-TCT0590R/R MMCT0590 IIT20241266ASHCT0590BCMANKG2ACAR